LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.

Hereditary cancer

Everyone has a risk for developing cancer...

Everyone has a risk for developing cancer. In many cases, the cause of the cancer can be hard to determine.

But in some cases, the reason cancer develops is in plain view: approximately 5%–10% ​of all cancers are thought to be caused by mutations in genes associated with hereditary cancer syndromes.1

If you’re wondering about hereditary cancers, we can help with genetic testing that can determine whether you have a mutation that increases your risk to develop certain cancers.

Should you be found to have an inherited mutation, more comprehensive medical management may be offered by your physician, including increased surveillance and screening for those cancers and the option of risk-reducing medical treatments and intervention.


The BRCA1 and BRCA2 (breast cancer 1 and 2) genes are two genes found within everyone’s genetic material. When mutations are found within these genes, they can cause an increased risk for several specific types of cancer, including breast cancer and ovarian cancer.2,3

BRCAssure can help provide information about your risk for developing breast, ovarian, or other cancers.



VistaSeq is a multi-gene assay for genetic mutations known to be associated with an increased risk of developing hereditary cancers. With 12 test panel options, the VistaSeq hereditary cancer portfolio allows you to have testing based on your personal or family history of cancer.

Ask questions about genetic testing options or results, or schedule an appointment.

About results logo

About your results

If you have already had a test performed, we can help answer questions about results.


  1. Family Cancer Syndromes. American Cancer Society website. Updated April 19, 2017. Accessed June 28, 2017.
  2. BRCA1. Genetics Home Reference. Available at: Accessed April 16, 2015.
  3. BRCA2. Genetics Home Reference. Available at: Accessed April 16, 2015.